Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 93

Similar articles for PubMed (Select 23150178)

1.

Serum soluble MICB (sMICB) correlates with disease progression and survival in melanoma patients.

Wu BJ, Li WP, Qian C, Ding W, Zhou ZW, Jiang H.

Tumour Biol. 2013 Feb;34(1):565-9. doi: 10.1007/s13277-012-0582-1. Epub 2012 Nov 14.

PMID:
23150178
2.

Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients.

Ugurel S, Rappl G, Tilgen W, Reinhold U.

Clin Cancer Res. 2001 May;7(5):1282-6.

3.

Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy.

Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U.

Cancer. 2001 Jul 15;92(2):369-76.

PMID:
11466692
4.

Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.

Wimmer I, Meyer JC, Seifert B, Dummer R, Flace A, Burg G.

Cancer Res. 1997 Nov 15;57(22):5073-6.

5.

Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients.

Rebmann V, Ugurel S, Tilgen W, Reinhold U, Grosse-Wilde H.

Int J Cancer. 2002 Aug 10;100(5):580-5.

PMID:
12124808
6.

Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.

Djukanovic D, Hofmann U, Sucker A, Rittgen W, Schadendorf D.

Anticancer Res. 2000 May-Jun;20(3B):2203-7.

PMID:
10928178
7.

Serum caspase-1 levels in metastatic melanoma patients: relationship with tumour burden and non-response to biochemotherapy.

Mouawad R, Antoine EC, Gil-Delgado M, Khayat D, Soubrane C.

Melanoma Res. 2002 Aug;12(4):343-8.

PMID:
12170183
8.

Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA.

Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR.

Cancer Immunol Immunother. 2006 Dec;55(12):1584-9. Epub 2006 Apr 25.

PMID:
16636811
9.
10.
11.

Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas.

Quaranta M, Divella R, Daniele A, Di Tardo S, Venneri MT, Lolli I, Troccoli G.

Tumori. 2007 May-Jun;93(3):275-80.

12.

Serum values of tumour necrosis factor-alpha and of soluble tumour necrosis factor-R55 in melanoma patients.

Ocvirk J, Stabuc B, Rudolf Z, Galvani V, Curin-Serbec V.

Melanoma Res. 2000 Jun;10(3):253-8.

PMID:
10890379
13.

Soluble intercellular adhesion molecule-1 and serum cytokines in melanoma patients treated with liposomes containing muramyl tripeptide.

Favaro D, Santarosa M, Quaia M, Spada A, Freschi A, Talamini R, Galligioni E.

Tumori. 1995 May-Jun;81(3):185-90.

PMID:
7571025
14.

Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.

Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, von der Maase H, Eggermont AM, Keilholz U; American Joint Committee on Cancer Stage IV Melanoma; EORTC 18951.

J Clin Oncol. 2007 Apr 20;25(12):1562-9.

16.
17.

Soluble MICB protein levels and platelet counts during hepatitis B virus infection and response to hepatocellular carcinoma treatment.

Tong HV, Song le H, Hoan NX, Cuong BK, Sy BT, Son HA, Quyet D, Binh VQ, Kremsner PG, Bock CT, Velavan TP, Toan NL.

BMC Infect Dis. 2015 Jan 23;15:25. doi: 10.1186/s12879-015-0754-x.

18.

Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism.

Holdenrieder S, Eichhorn P, Beuers U, Samtleben W, Stieber P, Nagel D, Peterfi A, Steinle A, Salih HR.

Anticancer Res. 2007 Jul-Aug;27(4A):2041-5.

19.

Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients.

Domingo-Domènech J, Castel T, Auge JM, Garcia-Albeniz XA, Conill C, Puig S, Vilella R, Matas J, Malvehy J, Gascón P, Mellado B, Molina R.

Tumour Biol. 2007;28(5):264-72. Epub 2007 Oct 26.

PMID:
17962723
20.

Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.

Paschen A, Sucker A, Hill B, Moll I, Zapatka M, Nguyen XD, Sim GC, Gutmann I, Hassel J, Becker JC, Steinle A, Schadendorf D, Ugurel S.

Clin Cancer Res. 2009 Aug 15;15(16):5208-15. doi: 10.1158/1078-0432.CCR-09-0886. Epub 2009 Aug 11.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk